On Monday, Novo Nordisk announced that the results from its Phase 3 trial investigating semaglutide as a treatment for Alzheimer’s “did not confirm the superiority of semaglutide versus placebo in the reduction of progression,” of the disease, according to the press release. Monday’s announcement had a silver lining. That is, the treatment did result in…